Rutika Mehta: consulting for Eli Lilly and Astellas, advisory board of Eli Lilly and Astellas, Novartis, BMS, Guardant Health, Boston Gene Speaker’s Bureau–Natera, and Daiichi Sankyo. This study was reviewed and approved by the Institutional Review Board at Moffitt Cancer Center. The major findings of this study have been presented as a Virtual Poster Grand Rounds Presentation at the Society of Surgical Oncology Meeting, 28 February to 3 March 2022.